Fluoxetine: a suitable long-term treatment

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Neuroscience

Background:

• Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for depression.
• Long-term safety data for SSRIs, particularly fluoxetine, are crucial for clinical decision-making.
• Understanding safety in special populations and during treatment cessation is essential.

Purpose of the Study:

• To review the safety profile of fluoxetine, focusing on long-term treatment.
• To compare fluoxetine's safety with other antidepressants, including tricyclic antidepressants and other SSRIs.
• To evaluate fluoxetine's safety in overdose and in pregnant women.

Main Methods:

• Systematic review of existing literature on fluoxetine safety.
• Analysis of adverse event rates and dropout rates.
• Examination of pregnancy outcome data following SSRI exposure.
• Assessment of discontinuation symptoms after fluoxetine interruption.

Main Results:

• Fluoxetine exhibits lower adverse events and dropout rates compared to tricyclic antidepressants and other SSRIs.
• No teratogenic effects were observed in prospective pregnancy outcome studies following SSRI/fluoxetine exposure.
• Discontinuation symptoms are absent or mild with fluoxetine, likely due to its long half-life.
• Fluoxetine demonstrates safety in overdose situations.

Conclusions:

• Fluoxetine possesses a favorable safety profile for long-term treatment.
• Its safety in overdose and pregnancy supports its suitability for diverse patient groups.
• The mild discontinuation profile enhances patient adherence and treatment continuity.